SCHEMBL19309166

SCHEMBL19309166

CC(C)c1nc(-c2cccc(S(=O)(=O)N3CCCC3)c2)cnc1N

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.53
CCNE2 O96020 2/20 0.49
CCNE1 P24864 2/20 0.49
CDK2 P24941 2/20 0.49
GSK3B P49841 2/20 0.49
ALDH1A1 P00352 6/20 0.49
GAA P10253 3/20 0.49
USP2 O75604 3/20 0.49
HPGD P15428 3/20 0.49
HSD17B10 Q99714 3/20 0.49
KDM4E B2RXH2 3/20 0.49
ESR1 P03372 1/20 0.49
GLA P06280 1/20 0.49
MAPT P10636 4/20 0.48
TSHR P16473 2/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
MAPK1 P28482 2/20 0.47
TRPV3 Q8NET8 2/20 0.46
PIK3CD O00329 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15308588 0.85 NPSR1 (0.58) NPSR1CCNE2CCNE1CDK2GSK3B
SCHEMBL16628980 0.83 NPSR1 (0.53) NPSR1CCNE2CCNE1CDK2GSK3B
SCHEMBL19309232 0.83 PIK3CD (0.48) GSK3BPIK3CDPIK3CAPIK3CGPIK3CB
SCHEMBL17718287 0.83 NPSR1 (0.53) NPSR1CCNE2CCNE1CDK2GSK3B
SCHEMBL19413037 0.80 KDM1A (0.52) PIK3CDPIK3CAPIK3CGPIK3CB
SCHEMBL15306544 0.75 NPSR1 (0.56) NPSR1ALDH1A1GAAUSP2HPGD
SCHEMBL3409495 0.74 GSK3B (0.63) CCNE2CCNE1CDK2GSK3BALDH1A1
SCHEMBL4008289 0.74 ATR (0.73) ALDH1A1HSD17B10KDM4EMAPTTSHR
SCHEMBL4015034 0.74 ATR (0.72) ALDH1A1HSD17B10KDM4EMAPTTSHR
SCHEMBL19309168 0.73 TYRO3 (0.67) ALDH1A1HSD17B10TSHRMAPK1PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10675286-B2 Heterocyclic compounds and uses thereof INFINITY PHARMACEUTICALS, INC. (US) 2020-06-09 US disclosed
US-20180055852-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF TWELVE THERAPEUTICS, INC. 2018-03-01 US disclosed
US-9751888-B2 Heterocyclic compounds and uses thereof INFINITY PHARMACEUTICALS, INC. (US) 2017-09-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10675286-B2 Heterocyclic compounds and uses thereof PIK3CA, PIK3CD, PIK3CB NPSR1 3761/4885CCNE2 2038/4885CCNE1 1333/4885
US-20180055852-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PIK3CA, PIK3CD, PIK3CB NPSR1 3761/4885CCNE2 2038/4885CCNE1 1333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.